Global Celiac Disease Market 2026-2035

Description

List of Tables

Celiac Disease Market Size, Share & Trends Analysis Report by Treatment Type (Vitamins and Dietary (Gluten-Free) Supplements, Steroids and Immunosuppressive Drugs, and Therapeutic Vaccines), By Diagnostic Type (Serologic Test, Genetic Testing, and Small-Bowel Biopsy) By End-User (Hospitals and Diagnostics Centers, and Research Institutes), Forecast Period (2026-2035)

Industry Overview

Celiac disease market was valued at $1,419.10 million in 2025 and is projected to reach $2,679.28 million by 2035, growing at a CAGR of 6.7% during the forecast period (2026-2035). The global celiac disease treatment market is advancing as public health agencies emphasize early screening and awareness programs. Educational initiatives have improved understanding of the disease's symptoms and long-term risks. As diagnostic procedures become more affordable and accessible, more individuals are being tested proactively. Collaboration between healthcare providers and research organizations has strengthened the detection network globally. Moreover, the expansion of digital health platforms is improving access to information and consultation.

Market Dynamics

Growing Demand for Gluten-Free Products

The global celiac disease market is witnessing significant growth due to the increasing demand for gluten-free foods among both diagnosed patients and health-conscious consumers. Rising awareness of celiac disease and gluten intolerance has led to a surge in product innovation within the food and beverage industry. Manufacturers are focusing on developing high-quality, nutritious, and palatable gluten-free alternatives. This trend is further supported by improved labeling regulations and the expansion of retail distribution channels worldwide. As a result, gluten-free products are transitioning from niche to mainstream markets.

Advancements in Diagnostic and Therapeutic Solutions

Technological advancements in diagnostic testing and the development of targeted therapies are shaping the future of the celiac disease market. Innovative serological and genetic testing methods are enabling earlier and more accurate detection of the disease. Pharmaceutical companies are actively investing in research to develop non-dietary treatment options that can improve patient outcomes. Moreover, the integration of digital health tools and telemedicine is enhancing disease management and patient monitoring. These advancements are expected to drive the market's growth and broaden access to effective care solutions.

celiac disease market size, share & trends analysis report by treatment type (vitamins and dietary (gluten-free) supplements, steroids and immunosuppressive drugs, and therapeutic vaccines), by diagnostic type (serologic test, genetic testing, and small-bowel biopsy) by end-user (hospitals and diagnostics centers, and research institutes), forecast period (2026-2035)

Market Segmentation

Based on the treatment type, the market is segmented into vitamins and dietary (gluten-free) supplements, steroids and immunosuppressive drugs, and therapeutic vaccines.
Based on diagnostic type, the market is segmented into serologic test, genetic testing, and small-bowel biopsy.
Based on the end-user, the market is segmented into hospitals and diagnostics centers, and research institutes.

Vitamins and Dietary (Gluten-Free) Supplements Segment to Lead the Market with the Largest Share

The global celiac disease market is expanding as consumers increasingly rely on gluten-free supplements to maintain nutritional balance. These products help individuals manage deficiencies caused by intestinal damage from gluten intolerance. Growing awareness of tailored dietary solutions has encouraged manufacturers to create innovative supplement formulations. Demand for fortified vitamins and minerals is rising among both diagnosed patients and health-conscious consumers. Advancements in ingredient sourcing and product labeling are also improving market accessibility. This shift toward personalized nutrition continues to strengthen the overall market outlook.

Hospitals and Diagnostic Centers: A Key Segment in Market Growth

Hospitals and diagnostic centers are driving market growth through the adoption of advanced testing technologies and improved patient care systems. Their role in early detection and continuous monitoring of celiac disease has increased treatment accuracy and efficiency. With access to modern diagnostic tools, healthcare providers can offer faster and more reliable test results. Many facilities are also integrating nutritional counseling and follow-up programs to enhance long-term management. Rising patient visits for gastrointestinal concerns have further supported this segment's expansion.

Regional Outlook

The global celiac disease market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Growing Regulatory Support and Consumer Awareness in Europe

The European celiac disease market is expanding as regulatory frameworks encourage early diagnosis and safe dietary alternatives. Health authorities across the region have implemented guidelines to ensure accurate labeling of gluten-free foods. Growing public awareness about gluten sensitivity has driven both clinical testing and product demand. Research funding from national agencies is fostering innovation in treatment and prevention strategies. Supermarkets and pharmaceutical outlets are also widening their gluten-free offerings to meet consumer needs. This combination of policy support and consumer engagement is driving consistent market growth across Europe.

North America Region Dominates the Market with Major Share

In North America, the celiac disease market is benefiting from well-established diagnostic infrastructure and a strong clinical research base. The region's focus on precision medicine and patient-centered care supports ongoing innovation in testing technologies. Increased government initiatives to promote gluten-free awareness have encouraged more routine screening. Hospitals and laboratories are continuously upgrading equipment to enhance diagnostic accuracy. The presence of key market players also ensures a steady pipeline of new products and therapies. These factors collectively reinforce North America's leading position in this field.

Market Players Outlook

The major companies operating in the global celiac disease market include Abbott Laboratories, Immco Diagnostics, Inc., Inova Diagnostics, Inc., Omega Diagnostics Group PLC, Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In May 2025, Teva Pharmaceutical Industries Ltd. announced that the US Food and Drug Administration (FDA) granted Fast Track designation to iinvestigationTEV-53408, an anti-IL-15 antibody, for the treatment of people with celiac disease who are on a gluten-free diet. TEV-53408 is currently being evaluated in a Phase 2a trial to assess the efficacy and safety in adults with celiac disease.
In January 2025, Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced positive symptom data from its Phase 2 ACeD-it trial evaluating its lead candidate, KAN-101, in individuals with celiac disease. The study data serves as the first symptomatic clinical proof of concept for KAN-101 and its potential as a disease-modifying treatment for celiac disease.

The Report Covers:

Market value data analysis of 2025 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global celiac disease market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023751

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Celiac Disease Market Sales Analysis - Treatment Type | Diagnostic Type | End-User ($ Million)
Celiac Disease Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Celiac Disease Market Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Celiac Disease Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Celiac Disease Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Restraints For Global Celiac Disease Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Celiac Disease Market Revenue and Share by Manufacturers
Celiac Disease Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Abbott Laboratories
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Immco Diagnostics, Inc.
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Inova Diagnostics, Inc.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Omega Diagnostics Group PLC
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Thermo Fisher Scientific Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Celiac Disease Market Sales Analysis by Treatment Type ($ Million)

5.1. Vitamins and Dietary (Gluten-Free) Supplements
5.2. Steroids and Immunosuppressive Drugs
5.3. Therapeutic Vaccines

6. Global Celiac Disease Market Sales Analysis by Diagnostic Type ($ Million)

6.1. Serologic Test
6.2. Genetic Testing
6.3. Small-Bowel Biopsy

7. Global Celiac Disease Market Sales Analysis by End-User ($ Million)

7.1. Hospitals and Diagnostics Centers
7.2. Research Institutes

8. Regional Analysis

8.1. North American Celiac Disease Market Sales Analysis - Treatment Type | Diagnostic Type | End-User | Country ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Celiac Disease Market Sales Analysis - Treatment Type | Diagnostic Type | End-User | Country ($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Celiac Disease Market Sales Analysis - Treatment Type | Diagnostic Type | End-User | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Celiac Disease Market Sales Analysis - Treatment Type | Diagnostic Type | End-User | Country ($ Million)
Macroeconomic Factors for Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. Abbott Laboratories
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
9.2. Barilla G. E. R. Fratelli S.p.A.
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. Bio-Rad Laboratories, Inc.
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. Conagra Brands, Inc.
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. Dr. Schar AG/S.p.A.
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. Euroimmun AG
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. General Mills, Inc.
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. Glutenostics, Inc.
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. Immco Diagnostics, Inc.
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. Inova Diagnostics, Inc.
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. J. Mitra & Co. Pvt. Ltd.
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. Kellogg Company
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. Nestle S.A.
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. Omega Diagnostics Group PLC
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. Pfizer Inc.
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. PRIMA Lab S.A.
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. Takeda Pharmaceutical Co., Ltd.
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. The Hain Celestial Group Inc.
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. The Kraft Heinz Company
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
9.20. Thermo Fisher Scientific Inc.
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies